Epizyme reported $27.53M in Sales Revenues for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Abbott ABT:US $ 11257M 638M
Agios Pharmaceuticals AGIO:US $ 5.58M 4.75M
Amarin AMRN:US $ 94.44M 0.19M
Amgen AMGN:US $ 6594M 356M
Biogen BIIB:US $ 2589.1M 57.3M
Bluebird Bio BLUE:US $ 1.52M 0.43M
Daiichi Sankyo 4568:JP Y 280317M 46392M
Eisai 4523:JP Y 184262M 6639M
Epizyme EPZM:US $ 27.53M 18.83M
Exelixis EXEL:US $ 419.43M 63.45M
Gilead Sciences GILD:US $ 6260M 330M
GlaxoSmithKline GSK:LN 6929M 2851M
Glaxosmithkline GSK:US $ 6929M 2851M
Karyopharm Therapeutics KPTI:US $ 39.68M 7.99M
Macrogenics MGNX:US $ 26.01M 14.91M
Merk MRK:US $ 14593M 1308M
Mirati Therapeutics MRTX:US $ 5.36M 4.65M
Novartis NOVN:VX SF 13085M 271M
Novartis NVS:US $ 13085M 271M
Pfizer PFE:US $ 27742M 2081M
Regeneron Pharmaceuticals REGN:US $ 2857.2M 107.9M
Seattle Genetics SGEN:US $ 497.5M 71.04M
Vertex Pharmaceuticals VRTX:US $ 2196.2M 98.7M
Xencor XNCR:US $ 30.18M 55.32M